ID: ALA4063407

Max Phase: Preclinical

Molecular Formula: C14H21N3O3S

Molecular Weight: 311.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)C[C@H](C(=O)NO)N1CCNc2cc(O)ccc2S1

Standard InChI:  InChI=1S/C14H21N3O3S/c1-9(2)7-12(14(19)16-20)17-6-5-15-11-8-10(18)3-4-13(11)21-17/h3-4,8-9,12,15,18,20H,5-7H2,1-2H3,(H,16,19)/t12-/m1/s1

Standard InChI Key:  CEEOEORRYAZYLP-GFCCVEGCSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 311.41

Molecular Weight (Monoisotopic): 311.1304

AlogP: 2.05

#Rotatable Bonds: 4

Polar Surface Area: 84.83

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.67

CX Basic pKa: 3.14

CX LogP: 1.42

CX LogD: 1.40

Aromatic Rings: 1

Heavy Atoms: 21

QED Weighted: 0.39

Np Likeness Score: -0.10

References

1. Ouvry G, Berton Y, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Chambon S, Comino C, Deprez B, Duvert D, Duvert G, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Pascau J, Pinto A, Polge G, Reitz A, Reversé K, Rosignoli C, Taquet N, Hennequin LF..  (2017)  Identification of novel TACE inhibitors compatible with topical application.,  27  (8): [PMID:28274635] [10.1016/j.bmcl.2017.02.035]

Source

Source(1):

• Scientific Literature